electroCore (ECOR) Q2 Revenue Jumps 20%

electroCore (NASDAQ:ECOR), a medical device company focused on non-invasive bioelectronic therapies, released its second quarter 2025 financial results on August 6, 2025. The release showed GAAP quarterly revenue of $7.381 million, narrowly surpassing analyst expectations of $7.24925 million (GAAP), and a record for the company. However, the GAAP net loss per share was $0.44, wider than the expected GAAP loss of $0.325 per share. Higher operating costs, notably in sales, marketing, and bad debt provisions, contributed to the GAAP earnings miss. While the period set a new high for GAAP net sales, rising costs and continued dependence on government contracts present ongoing challenges. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. electroCore specializes in non-invasive neuromodulation devices for chronic pain syndromes. Its flagship product, gammaCore, is a handheld vagus nerve stimulator designed to reduce symptoms of headache and migraine, and is cleared by the United States Food and Drug Administration (FDA) for multiple indications.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool